OBA Professional Development & CBA Biotechnology Committee PROGRAM | Original Program Date: October 26, 2018

Our genome is personal, so shouldn’t our medicine be as well? As the pace of development in personalized or precision medicine accelerates, many new issues and challenges arise out of the ethical and practical implications around privacy, access, and ownership of personal genomic data. What is the true value of personalized medicine and who pays for it? What technology or information can be protected with patents or other rights? Whether you are in-house counsel or in private practice, this innovative program will tackle these questions and provide insightful answers.

Join us for this unique and valuable program.

PROGRAM CHAIRS

Geoff Mowatt, DLA Piper (Canada) LLP
Inta Gaikis, Novo Nordisk Canada

AGENDA

To view the full program agenda, please click here.